Released Mar 13, 2024, after the close
10-K filed Mar 13, 2024, 73 days after period end · 0000950170-24-030767
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$223.00K$223.00K derived−19.8% vs Q4 2022+2.3% vs Q3 2023
Net Income$51.21M$51.21M derived+91.2% vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$50,532,000+94.9%
Operating Cash Flowderived-$17,493,000N/M
Margins · derived
Operating margin22660.1%
Net margin22962.3%
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $223.00K | $278.00K | — | $0.00 |
| Net Income | $51.21M | $26.79M | -$29.30M | -$18.60M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR